Cytosine β-D-arabinofuranoside hydrochloride is an anti-leukemic agent which binds to topoisomerase I, resulting in DNA fragmentation and inhibition of replication. This compound does not have any effects on RNA synthesis. Cytosine β-D-arabinofuranoside hydrochloride functions as a ligand with strong affinity and selectivity for the translocator protein (TSPO). Studies suggest that cytosine β-D-arabinofuranoside hydrochloride can down-regulate deoxycytidine kinase in acute myeloid leukemia murine cell lines, which inhibits the phosphorylation of several deoxyribonucleosides. Furthermore, cytosine β-D-arabinofuranoside hydrochloride can be inhibited in myeloid leukemic cells via suppression of ENT1 promoter activity, responsible for transporting cytosine β-D-arabinofuranoside into the cell.
1. Jin, G., et al. 2009. Biochem. Biophys. Res. Commun. 390: 1001-1006. PMID: 19853583
2. Rathe, S.K. and Largaespada, D.A. 2010. Leukemia. 24: 1513-1515. PMID: 20508618
3. Denora, N., et al. 2010. Mol. Pharm. 7: 2255-2269. PMID: 20958082
See how others have used Cytosine β-D-arabinofuranoside hydrochloride. Click on the entry to view the PubMed entry .
PMID: # 24375454 2014. Eur. J. Immunol. 44: 1108-18.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.